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Abstract
The use of Papanicolaou smears for cervical cancer
screening has led to an increased detection of preinvasive
conditions of the cervix, cervical intraepithelial neoplasia
(CIN). Epidemiological studies have shown an association
between low levels of dietary /3-carotene and CIN. In this
Phase II study, we have explored the effect of p.o. 13-
carotene administration on CIN I and II. Patients with
documented CIN I or II were treated with 30 mg daily of
13-carotene for 6 months. Response rates were determined
at 0, 3, 6, and 12 months with cytology, colposcopy, and/
or biopsies. Levels of 13-carotene and vitamin E were
determined at the same time intervals in vaginal mucosa
cells and serum. Response rates were 18 of 30 (60%), 21
of 30 (70%), and 10 of 30 (33%) at 3, 6, and 12 months,
respectively. Significant changes occurred in the serum
13-carotene levels over time. Median levels over 2200 mg/
ml were found at 3 and 6 months versus a baseline
median level of 111 (P < 0.0001). Significant increases
were also noted in the 13-carotene levels of the vaginal
mucosa compared to baseline (P 0.01) and a significant
correlation was noted between serum and vaginal 13-
carotene levels as well (P < 0.0001). This study indicates
that a large percentage of patients with CIN I and II will
respond clinically to p.o. 13-carotene supplementation.
There is a positive relationship between serum and tissue
levels of 13-carotene which suggests that serum levels can
be used for monitoring purposes. Because of these
encouraging results, prospective randomized studies are
ongoing comparing the efficacy of 13-carotene against an
untreated control arm.
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Introduction
Carcinoma of the cervix is one of the most common and deadly
malignancies in the developing world. In some countries, it is
the leading cause of death for women between the ages of 30
and 50. In the United States, the incidence and mortality rate of
cervix cancer has declined over the last few decades with
approximately 13,000 women developing the disease and 6,000
dying annually. This decreasing incidence is attributed to the
effectiveness of screening programs. Because of a well-estab-
lished premalignant phase, ease of use of Pap smears, low cost,
and a high degree of acceptability, screening programs have
been extremely successful in decreasing the incidence of inva-
sive cervix cancer. However, the success of this program has
led to a significant increase in the detection of CIN.3 Because
of the easy accessibility for biopsy and inspection, cancer of the
cervix is an ideal tumor for the study of chemopreventive
agents.
An association has been found between the incidence of
CIN and dietary levels of vitamin A and/or /3-carotene (1-4).
The risk of cervical cancer was also found to be higher among
women with lower serum levels of total carotenoids (4). /3-car-
otene has been used with success in the management of pre-
malignant lesions such as p.o. leukoplakia (5, 6).
Previous clinical trials have demonstrated the potential use
of topical /3-trans-retinoic acid in the management of CIN (7,
8). However, local toxicity was commonly experienced. In
contrast, /3-carotene has been found to be relatively nontoxic to
humans; at high doses, a slight yellowing of the skin may occur.
Because of this lack of side effects, /3-carotene has received
attention as a chemopreventive agent. In this Phase II trial, we
have obtained preliminary data on the effect of /3-carotene on
CIN. In addition, we investigated the relationship between the
serum and tissue levels of micronutrients and their response to
p.o. /3-carotene supplementation.
Materials and Methods
This nonrandomized Phase II study was intended to determine
the activity and side effects of /3-carotene in the management of
patients with CIN I and II.
Eligibility criteria for study entry were the presence of an
intraepithelial lesion recognizable using colposcopy and docu-
mented by biopsy as CIN I or II. Eligible patients had residual
lesion or lesions remaining on the cervix following the biopsy.
Patients with positive endocervical curettetage on previous or
concomitant examinations were not eligible for this protocol.
Also ineligible were patients who had been exposed in utero to
diethylstilbestrol. All patients underwent initial cervical cytol-
ogy and colposcopy with mapping of the cervical lesion on
appropriate forms. All colposcopies were performed either by a
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gynecological oncologist or a gynecological oncology fellow.
Standard criteria for evaluation of CIN were used by both
investigators. Quadrant extension of the lesion was also noted.
Colposcopically directed biopsies were performed in all pa-
tients. An informed consent approved by the Institutional Re-
view Board at University of California, Irvine was signed by all
patients.
Pathologists who were blinded as to the patients’ partici-
pation in the study graded the biopsies as normal or CIN 1, 2,
or 3.
Vaginal and serum levels of /3-carotene, retinol, and vita-
mm E were determined at 0, 3, 6, and 12 months. Analysis was
performed as described previously (9). Serum samples were
obtained on 86 of 122 (70%) of the total patient visits. The
majority of missing samples (23/36) occurred among the first
I 0 patients because of a technical failure. Cervical-vaginal cell
samples were obtained from 16 patients in 46 of52 (88%) visits
during the second half of the study. A cytobrush was used to
collect cells from the vaginal wall. The cells were stored and
transported in saline solution at 4#{176}C.
Patients received 30 mg/day of /3-carotene for 6 months
and were assessed for extent of disease at baseline and for
response at 3, 6, 9, and 12 months. Pap smears were routinely
performed at each follow-up visit. All patients had biopsies at
baseline. At subsequent visits, biopsies were only performed if
the colposcopy suggested progression of the dysplasia. If pro-
gression was confirmed, patients were then removed from the
study and considered treatment failures. Patients with stable
disease at 9 months were removed from study and treated
conventionally. Patients who achieved a response were fol-
lowed for an additional 6 months off therapy.
Patients were considered responders if the Pap smear and
colposcopy reversed to normal. In cases with negative Pap
smears but suspicious colposcopy, biopsies were taken to de-
termine response. All patients with abnormal Pap smears or
positive biopsies were considered to be nonresponders.
Statistical Methods. Comparison of response probability by
disease stage or extent (quadrants involved) were made using
the Fisher exact test. To avoid introducing a bias due to patient
drop-off, patients who dropped off study were considered to be
nonresponders at all subsequent times. The Kruskal-Wallis test
was used to compare micronutrient levels with time. Correla-
tions were assessed using the Spearman rank correlation
method. The interquartile range gives the 25th and 75th per-
centile values for the variable being described, thus providing
the limits for the central half of the data.
Cell counts from fresh cervical-vaginal cells were scored
as < I , I , 2, or 3 million cells. When the number of cells was
reported as <1 million (n = 15), 0.7 million was used. Since
the lowest observed /3-carotene level was 0.10 ng/million cells,
a value of 0.05 ng/million cells was used in the 14 instances
when the level was not detectable. Formal comparison of the
serum micronutrient and cellular /3-carotene levels was done
only in the patients for whom data both on (3 or 6 months) and
off (0, 9, or I 2 months) /3-carotene supplementation was avail-
able using the Wilcoxon signed rank test. Whenever multiple
levels were available for a patient, the values were averaged.
Results
Of the 30 patients enrolled in the trial, five patients were taken
off the study due to either disease progression (two at 3 months
and one at 6 months) or persistent disease at 9 months (n = 2).
Three additional patients were removed from the study due to
pregnancy (one at 3 months and 2 at 6 months). Five patients
Table I Response and number of quadrants involved
Quadrant
Responders
6mo l2mo
1-2 19/22(86%) 10/22(45%)
3-4 2/8 (25%)
P = 0.003”
0/8 (0%)
P = 0.03”
C’ Comparison of one to two vs. three to four quadrants using the two-sided Fisher
exact test.
dropped off from the study because of relocation (one at 3
months and four at 6 months).
At 6 months, 21 patients (70%) were responders (95%
confidence interval, 51-85%), whereas at 1 year 10 patients
(33%) were responders (95% confidence interval, 17-53%). Of
the 1 1 patients who were responders at 6 months but not at 1
year, 6 had recurrence of dysplasia and 5 were patients who
dropped off the study. One of the patients who withdrew at 6
months had CIN II dysplasia at baseline but was biopsy neg-
ative at 6 months.
Patients were requested to report the number of pills not
taken, every 3 months. Compliance was good with all patients
able to take /3-carotene as prescribed. This was further con-
firmed by significant elevation of /3-carotene serum levels on
all patients tested. No side effects were reported by any of the
patients participating in the study. None of the patients who
dropped off did so because of side effects. The severity of
disease was not significantly associated with the probability of
response: 14 of 18 (78%) patients with CIN I were responders
at 6 months compared to 7 of 1 2 (58%) patients with CIN II
(P = 0.42) and 6 of 1 8 (33%) patients with CIN I were
responders at 12 months compared to 4 of 12 (33%) patients
with CIN II (P 1.0).
The likelihood of response did depend on disease extent as
measured by the number of quadrants (quadrants 1-4) of the
cervix involved with CIN. Nineteen of 22 patients (86%) with
one to two quadrants involved had responded at 6 months
versus 2 of 8 patients (25%) with three- to four-quadrant
involvement (P 0.003). Ten of 22 patients (45%) with one to
two quadrants involved were responders at 12 months com-
pared to 0 of 8 patients with three to four quadrants involved
(P = 0.03; Table 1). Of the patients who dropped off the study
at 3 and 6 months, two of two and one of six had disease
involvement in three or four quadrants. Both tests remain sta-
tistically significant even if the patients who dropped off the
study were excluded from the analysis.
Serum /3-carotene levels were significantly higher when
the patients were receiving /3-carotene supplementation (P =
0.0001) using the Wilcoxon signed rank test for paired data.
The median baseline serum /3-carotene level was 1 1 1 ng/ml,
with one half of the patients having values between 62 and 159
ng/ml (Table 2). This level increased to roughly 2300 at 3 and
6 months when the patients took /3-carotene supplementation.
The serum levels declined to 412 at 9 months and 243 at 12
months, values still substantially higher than baseline levels
(P = 0.003 and P = 0.004) Vitamin E levels were also higher
at 3 and 6 months (P = 0.0004), but no difference in retinol
levels was noted (P = 0.91 ; Table 2). Strong correlations were
noted between baseline and 12 months for /3-carotene, retinol,
and vitamin E (r = 0.87, 0.90, and 0.82, respectively; n = 10).
Correlation between the baseline serum /3-carotene levels and
after 6 months is much lower (r = 0.39). There was no signif-
icant relationship between the serum level of /3-carotene and
response.
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Fig. 1 . Plot of serum versus vaginal 13-carotene (,i 43). -, linear regression
fit; - - - -, 95% confidence interval.
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Table 2 Serum m icronutrient levels
Time (mo) ,i Md (ng/mI) Interquartile range Range
13-Carotene
0 18 111 62-159 22-324
3 21 2254 1198-3252 94-4653
6 20 2270 1718-3344 58-4078
9 13 412 216-478 52-1222
12 12 243 146-360 71-391
Retinol
0 18 400 353-531 176-693
3 21 450 393-595 229-710
6 20 485 408-540 198-708
9 14 505 416-587 282-722
12 13 445 353-505 264-723
Vitamin E
0 18 8979 6993-10111 3930-13324
3 21 9327 8523-11681 5087-18545
6 20 9315 8630-10903 4920-18305
9 14 8787 8050-9889 5216-14232
12 13 8771 7641-10277 5165-12651
Fig. 1 shows the relationship between the logarithm of
serum and vaginal /3-carotene levels for 43 samples (r 0.75).
Eleven patients had /3-carotene levels measured on cervical-
vaginal cells both on (3 or 6 months) and off (0, 9, or 12
months) /3-carotene supplementation (Fig. 2). The /3-carotene
level, which rose in 10 of the 1 1 patients, showed a statistically
significant increase when patients were on supplementation
(P = 0.007). The lone patient with a reduced vaginal /3-caro-
tene level also had a lower serum /3-carotene at 3 and 6 months
Log Serum Beta Carotene (ng/ml)
Beta Carotene Supplementation
Fig. 2. Plot of vaginal 13-carotene by 13-carotene supplementation in I I patients
who were studied both on and off /3-carotene. Lines join data from the same
patient.
compared to baseline levels. (In one patient, no comparison of
serum /3-carotene was possible and in the remaining nine pa-
tients the level rose while on supplementation.) Thus, it is likely
that this patient did not take /3-carotene supplementation as
instructed.
Discussion
These results suggest that a significant percentage of patients
with CIN will respond to /3-carotene supplement at a dose of 30
mg daily. Seventy percent of the patients (21/30) at 6 months
and 30% (10/30) at 12 months exhibited a response of their CIN
to /3-carotene. Five patients who were complete responders
dropped out of the study at 6 months due to pregnancy or other
reasons, which impacted the total percentage of responders at
I 2 months. Eighteen patients were considered responders at 3
months. This increased to 2 1 at 6 months. Only one patient who
was a responder at 3 months recurred between 3 and 6 months.
However, six patients recurred between 6 and 12 months. (After
/3-carotene supplementation was discontinued.) Nevertheless,
10 of 16 patients who were responders at 6 months and com-
pleted the protocol continued to respond after 12 months. Thus,
we might anticipate that three of the five responders who
dropped off at 6 months would have been responders at 12
months had they remained on study. Hence, we estimate the
true response rate at 12 months to be about 43% (13/30). In
contrast, deVet et a!. (I 1 ) were not able to show a beneficial
effect of /3-carotene on the regression rate of cervical dysplasia.
However, in their study, patients were treated with only 10 mg
of /3-carotene daily for 3 months.
932 .Carotene Treatment
14. Richart, R. M., and Barron, B. A. A follow-up study of patients with cervical
dysplasia. Am. J. Obstet. Gynecol., /05: 383-393, 1969.
We were also able to demonstrate that increased intake of
/3-carotene translated into significant increases in serum and
vaginal cell levels.
In this study, we also found a difference in the response
rate to /3-carotene according to the number of quadrants of the
cervix involved. Patients with small lesions occupying only one
and two quadrants responded better than patients with larger
lesions. This indicates that in future studies surface extension of
the lesion in addition to the degree of dysplasia should be
considered as a stratification factor at the time of study entry.
The end points selected in this study closely adhere to the
present standard of care. Patients with abnormal Pap smears
and/or abnormal colposcopies underwent cervical biopsies. Pa-
tients with normal Pap smears and colposcopies did not un-
dergo biopsies but continued to be maintained with cytology
and colposcopy. This could be viewed as a limitation of this
study since not all patients were biopsied. However, it is the
unusual patient that will show dysplasia on random cervical
biopsies in the absence of abnormalities in the Pap smear or
colposcopy.
Although the outcome of this Phase II study is encourag-
ing, the interpretation is difficult due to the variable rate (0-
60%) of the spontaneous regression for CIN seen in different
populations ( I 2, 13). In general, the lowest report of regression
rates were from studies where the original diagnosis, as well as
the follow-up, has been performed using cytology and colpos-
copy exclusive of cervical biopsies in contrast to higher regres-
sion rates reported by investigators making the diagnosis and
following up patients with cervical biopsies. There is the pos-
sibility that single-punch biopsy not only removes the lesion,
but also beneficially influences the remaining epithelium (14).
Because of the variable regression rate for low-grade CIN, a
prospective randomized study will need to be completed to
determine whether /3-carotene has efficacy in the management
of CIN, a trial currently ongoing at our institution.
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